Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
194 results about "Airway inflammation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Airway inflammation is a state of irritation in the airways where the immune system responds to a perceived threat and causes swelling, itching, redness, and other symptoms. A number of respiratory diseases are associated with inflammation of the airway, either as a symptom or cause.
Inhibition of factor B, the alternative complement pathway and methods related thereto
InactiveUS20050260198A1Reduce or prevent airway hyperresponsiveness (AHR) or airway inflammationSenses disorderAntibody mimetics/scaffoldsReperfusion injuryMedicine
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and / or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
Owner:MUSC FOUND FOR RES DEV +2
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
ActiveUS20090060898A1Avoid immune responseInhibitory activityOrganic active ingredientsAntipyreticTlr agonistsAutoimmune disease
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Owner:IDERA PHARMA INC
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
ActiveUS20120128699A1Antagonize inhibit suppress preventAntagonize, inhibit suppress or prevent the cytokine and chemokine responseNervous disorderAntipyreticTlr agonistsAutoimmune disease
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These TROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Owner:IDERA PHARMA INC
Inhibition of factor B, the alternative complement pathway and methods related thereto
InactiveUS20080075720A1Reduce or prevent airway hyperresponsiveness (AHR) or airway inflammationSenses disorderAntibody mimetics/scaffoldsReperfusion injuryMedicine
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and / or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
Owner:NAT JEWISH HEALTH +2
Local nasal immunotherapy for allergen-induced airway inflammation
InactiveUS20040071718A1Inhibited free radical formationReducing airway inflammationAllergen ingredientsAnesthesiaImmunotherapy
Methods and pharmaceutical compositions for treating allergen-induced airway inflammation. The method includes administering a therapeutically effective amount of a pharmaceutical composition comprising a Dermatophoides pteronyssinus group 2 (Dp2) epitope peptide and a pharmaceutically acceptable carrier to an individual having allergen-induced airway inflammation, in a manner consistent with local nasal immunotherapy.
Owner:TSAI JAW JI
Method for treating airway disorders
InactiveUS20050053549A1Compounds screening/testingDiagnostic recording/measuringDiseasePatient compliance
A method for management of asthma and other respiratory conditions is disclosed. This method uses exhaled nitric oxide readings to measure airway inflammation, thereby allowing precise titration of medication. The present invention can also be used to measure patient compliance with prescribed treatment regimes.
Owner:AEROCRINE AB
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
ActiveUS20090087388A1Avoid immune responseInhibitory activityOrganic active ingredientsCosmetic preparationsTlr agonistsAutoimmune disease
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Owner:IDERA PHARMA INC
Therapeutic Method
The present invention relates generally to a method of modulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of modulating an inflammatory response in a mammal by modulating the functional activity of activin and thereby modulating the pro-inflammatory mediator cascade. The method of the present invention is useful, inter alia, in the treatment and / or prophylaxis of conditions characterised by an aberrant, unwanted or otherwise inappropriate inflammatory response including, inter alia, sepsis and inflammation of the airway. The present invention is further directed to methods for identifying and / or designing agents capable of modulating activin mediated regulation of the inflammatory response.
Owner:PARANTA BIOSCI
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Owner:IDERA PHARMA INC
Collecting device of exhaled breath condensate (EBC)
InactiveCN101238980ASolve the automatic separationAddressing the effects of entry into refrigeration zonesWithdrawing sample devicesDiagnostic recording/measuringOxidative stressEngineering
The invention relates to a EBC detection as a detection technique completely without wound, with important use value for airway inflammation. A fourway gaspath solves the automatic separation of entrance of expired air, exit of expired air, inspired air and spit residue. The upbending design and 'claw type' of the exit pipeline of the expired air can solve the effect of spit residue from the expired air on refrigeration area. A singlechip system detects the expired air amount and the condensing temperature is set to quantify the collection of the condensate of expired air, so as to quantitatively evaluate change and degree of states such as oxidation stress, inflammation and the like in airway of a variety of respiratory disease.
Owner:JILIN UNIV
Anti-migraine spirocycles
The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
Owner:BRISTOL MYERS SQUIBB CO
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Owner:IDERA PHARMA INC
Therapeutic agents for the treatment of migraine
The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
Owner:BRISTOL MYERS SQUIBB CO
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Owner:IDERA PHARMA INC
Anti-TNFalpha antibodies in therapy of asthma
The present invention provides for uses of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in the treatment of asthma or airway inflammation in an individual in need thereof. The present invention also provides for use of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in reducing accumulation in lungs of inflammatory cells in an individual in need thereof.
Owner:TREACY GEORGE
Inhibition of factor b, the alternative complement pathway and methods related thereto
InactiveUS20080102040A1Reduce or prevent airway hyperresponsiveness (AHR) or airway inflammationPowder deliverySenses disorderReperfusion injuryMedicine
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and / or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
Owner:MUSC FOUND FOR RES DEV +2
Method of prophylaxis and agents for use therein
InactiveUS20110014292A1Powder deliverySynthetic polymeric active ingredientsAntigenAllergic airway inflammation
The present invention relates generally to a method of prophylactically or therapeutically treating antigen-induced airway tissue inflammation and agents for use therein. More particularly, the present invention provides a method of prophylactically or therapeutically treating allergic airway inflammation and agents for use therein via the administration of the method of the present invention is useful, inter alia, in the treatment and / or prophylaxis of conditions characterised by antigen-induced airway tissue inflammation.
Owner:COOP RES CENT FOR ASTHMA
Herbal composition and method for treatment of airway inflammation using the same
An herbal composition includes Dioscorea opposita, Nelumbo nucifera seeds, Euryale ferox seeds, Poria cocos, Diospyros kaki, Prunus dulcis, Mentha piperita leaves, and Panax quinquefolius. A method for treatment of airway inflammation in a mammal includes administering to the mammal in need of such treatment the aforesaid herbal composition.
Owner:TAICHUNG VETERANS GENERAL HOSPITAL
Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
(Neuro)protectin D1 (1OR,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid) and 15,16-dehydro-PD1 and their derivatives are useful in the treatment of airway inflammation, especially asthma.
Owner:UNIV OF SOUTHERN CALIFORNIA +1
Fc Coupled Compositions and Methods of Their Use
InactiveUS20150004161A1Lower immune responseImmunoglobulin superfamilyPeptide/protein ingredientsAntigenImmunotherapeutic agent
Disclosed are compositions comprising an Fc portion of IgE coupled to an agent. For example, disclosed are compositions comprising an Fc portion of IgE coupled to an antigen or immunotherapeutic. These compositions can be used as a vaccine or an immunotherapeutic. Thus, these compositions can modulate the immune system by both increasing and decreasing the immune response. The Fc portion of IgE can bind to CD23 and transport the antigen or immunotherapeutic across airway epithelial cells. Disclosed are methods of treating airway inflammation with compositions comprising an Fc portion of IgE coupled to an antigen or immunotherapeutic.
Owner:UNIV OF MARYLAND
Modulation of airway inflammation in patients with cystic fibrosis and related diseases
InactiveUS20050113443A1Ameliorating pathogenic inflammatory responseEasy to controlBiocideAnimal repellantsNeutrophil granulocyteLipoxin
This invention provides a method for treating pulmonary disease in patients with cystic fibrosis, variant cystic fibrosis, and non-cystic fibrosis bronchiectasis. The method involves administering a pharmaceutically effective amount of a lipoxin or lipoxin analogue to subjects with cystic fibrosis or related disease, in amounts sufficient to downregulate harmful neutrophilic airway inflammatory responses.
Owner:KARP CHRISTOPHER L +1
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Owner:IDERA PHARMA INC
Local nasal immunotherapy with allergen strip for allergic rhinitis
InactiveUS6994870B2Safe and effectiveGenetic material ingredientsSnake antigen ingredientsNasal cavityNonallergic rhinitis
A method and strip for treating allergen-induced airway inflammation. The method includes applying a nasal or skin strip containing a mixture of an allergen and a pharmaceutically acceptable carrier to an individual having allergen-induced airway inflammation in a manner consistent with local nasal immunotherapy.
Owner:TSAI JAW JI
Method of treating respiratory disorders and airway inflammation
Compositions and methods for treating or preventing respiratory disorders and airway inflammation in an animal are disclosed. In one embodiment, the respiratory disorder is asthma. In one embodiment, the airway inflammation is asthma-related. In one embodiment, the respiratory disorder is cystic fibrosis. The method comprises administering an electrolyzed saline solution to the animal. In one embodiment, the electrolyzed saline solution comprises about 0.1 ppm to about 100 ppm ozone and one or more active species selected from the group consisting of: about 5 ppm to about 300 ppm of at least one active chlorine species, about 0.1 ppm to about 300 ppm of at least one active oxygen species, about 5 ppm to about 300 ppm active hydrogen species, and combinations thereof. A mouse model of cystic fibrosis and methods of screening pharmaceutical agents are also provided.
Owner:REOXCYN INNOVATION GRP LLC
Compositions and methods for treating inflammatory bowel disease and airway inflammation
Provided are compositions and methods for treating inflammation due to an immune response. Non-limiting example compositions include class-2 SPATE proteins that are capable of cleaving proteins involved in an inflammatory immune response in a patient. Example compositions include at least one mucin-cleaving class-2 SPATE protein. Further example compositions include protein involved in intestinal colonization (Pic). Non-limiting example methods include methods of decreasing inflammation in a patient having inflammation and methods of perturbing immune response in a patient having a disease or condition in which an active immune response is attributable to a cause of the disease or condition, by administering to the patient a composition including at least one class-2 SPATE protein capable of cleaving proteins involved in an inflammatory immune response.
Owner:UNIV OF MARYLAND
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
ActiveUS8486908B2Antagonize, inhibit suppress or prevent the cytokine and chemokine responseOrganic active ingredientsPeptide/protein ingredientsTlr agonistsAllergy
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Owner:IDERA PHARMA INC
An agent comprising fgf2 as an effective ingredient for treatment or prevention of asthma and chronic obstructive pulmonary disease
The present invention relates an agent comprising FGF2(Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor(bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease(COPD). Also, The present invention relates Th1 asthma and COPD mouse animal model induced by Ovalbumin and double strand RNA. The therapeutic agent comprising FGF2 of the present invention can be used for treatment or prevention for airway fibrosis, airway inflammation, airway hyperresponsiveness, airway remodeling, asthma and COPD. Also, Th1 asthma and COPD mice animal model induced by Ovalbumin and double strand RNA can be used for development of therapeutic agent for asthma and COPD.
Owner:MD HEALTHCARE INC
Anti-inflammatory compositions for treating brain inflammation
InactiveUS20130028864A1Promote absorptionOrganic active ingredientsBiocidePhospholipidInterferon alpha
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containing one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRR, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT
Signal transduction pathway modulation
InactiveUS20130309238A1Abolished airway hyperresponsivenessSuppressed airway inflammationCompound screeningBiocideCytokineExacerbation
Provided herein are methods and compositions for modulating signal transduction pathways by regulating the expression and / or activity of Midline-1, enabling the inhibition of airways inflammation, the inhibition of airways hyperresponsiveness, the inhibition of rhinovirus-associated inflammation, and reductions in cytokine and chemokine release. Methods and compositions disclosed herein facilitate the treatment and prevention of conditions associated with airway inflammation, airway tissue remodelling and rhinovirus-associated inflammation and symptoms, manifestations and exacerbations thereof, in particular of allergic diseases such as allergic airways diseases including asthma.
Owner:NEWCASTE INNOVATION LTD
N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt
Disclosed is a hemisulfate salt of Compound (I):and crystalline forms of the hemisulfate salt. Also disclosed are methods of using the hemisulfate salt of Compound (I) as a CGRP receptor antagonist, and pharmaceutical compositions comprising the hemisulfate salt of Compound (I). The hemisulfate salt of Compound (I) is useful in treating, preventing, or ameliorating disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
![N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt](https://images-eureka.patsnap.com/patent_img/a8c6b452-41ee-47ab-ac0c-30e428e143e4/US08759372-20140624-D00001.png "N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt")
![N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt](https://images-eureka.patsnap.com/patent_img/a8c6b452-41ee-47ab-ac0c-30e428e143e4/US08759372-20140624-D00002.png "N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt")
![N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt](https://images-eureka.patsnap.com/patent_img/a8c6b452-41ee-47ab-ac0c-30e428e143e4/US08759372-20140624-D00003.png "N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt")
Owner:BRISTOL MYERS SQUIBB CO
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com